Insights on the Continuous Glucose Monitoring Device Global Market to 2026 - Featuring Abbott Laboratories, Medtronic & Novo Nordisk Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Global Continuous Glucose Monitoring Device Market By Component, By End User, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Continuous Glucose Monitoring Device Market size is expected to reach $8.5 billion by 2026, rising at a market growth of 12.4% CAGR during the forecast period.

Continuous Glucose Monitoring (CGM) is one of the newest advances in diabetes management technology. CGM system is a kind of glucose monitoring device that uses the transcutaneous or subcutaneous route to insert a biosensor. The embedded sensor measures the levels of glucose in interstitial fluid or blood and transmits the information to a receiver/monitor for display of results using a transmitter. Due to their related many benefits over other glucose control devices these systems play an important role in diabetes management.

Continuous glucose monitors (CGMs) are widely available and efficient as a tool for real-time biofeedback and behavioral improvement for individuals with type 2 diabetes (T2D), and also those with prediabetes. A convergence of many megatrends in healthcare will lead to the ever more frequent use of CGM in people with T2D and even prediabetes. This will also further boost the precision, size, and cost of CGM; include the option to transfer data to the cloud. The integration will ensure the availability of digital coaching methods and computational applications, and eventually, artificial intelligence and a change to value-based treatment will follow.

CGM devices provide beneficial insights into the effects of meals, exercises, and diseases that affect the glucose level of an individual and reduce the risk of hyperglycemia and hypoglycemia. The global spread of diabetes epidemic coupled with aging demographics & ongoing technological advances in this area has boosted demand for CGM devices and therefore catalyzed the growth of the market for CGM devices.

Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

Companies Profiled:

  • Abbott Laboratories
  • Medtronic PLC
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • DexCom, Inc.
  • Ypsomed AG
  • Senseonics Holdings, Inc.
  • GlySens, Incorporated
  • A. Menarini Diagnostics Ltd. (The Menarini Group)
  • Echo Therapeutics, Inc.
  • Johnson and Johnson

Unique Offerings from the Publisher:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

2.1 Introduction

2.1.1 Overview

2.1.2 Market Composition and Scenario

2.2 Key Factors Impacting the Market

2.2.1 Market Drivers

2.2.2 Market Restraints

Chapter 3. Global Continuous Glucose Monitoring Device Market by Component

3.1 Global Sensors Market by Region

3.2 Global Transmitters Market by Region

3.3 Global Receivers Market by Region

Chapter 4. Global Continuous Glucose Monitoring Device Market by End-user

4.1 Global Hospitals Continuous Glucose Monitoring Device Market by Region

4.2 Global Homecare Settings Market by Region

4.3 Global Other End Users Market by Region

Chapter 5. Global Continuous Glucose Monitoring Device Market by Region

5.1 North America Continuous Glucose Monitoring Device Market

5.2 Europe Continuous Glucose Monitoring Device Market

Chapter 6. Europe Continuous Glucose Monitoring Device Market by Country

Chapter 7. Company Profiles

7.1 Abbott Laboratories

7.1.1 Company Overview

7.1.2 Financial Analysis

7.1.3 Segmental and Regional Analysis

7.1.4 Research & Development Expense

7.1.5 Recent strategies and developments:

7.1.5.1 Partnerships, Collaborations, and Agreements:

7.1.5.2 Product Launches and Product Expansions:

7.2 Medtronic PLC

7.3 F. Hoffmann-La Roche Ltd.

7.4 Novo Nordisk A/S

7.5 DexCom, Inc.

7.6 Ypsomed AG

7.7 Senseonics Holdings, Inc.

7.8 GlySens, Incorporated

7.9 A. Menarini Diagnostics Ltd. (The Menarini Group)

7.10 Echo Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/qtjjoa

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900